Swissmedic
REGULATORY UPDATE
Revision of the Guidance document Authorisation Biosimilar
Published: 10/1/2026Detected: 10/1/2026
Summary preview
Revision of the Swissmedic guidance for authorisation of biosimilars may refine the regulatory expectations for demonstrating biosimilarity, including how applicants structure supporting evidence.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
manufacturing
quality
clinical
safety
labeling
#biosimilar
#Swissmedic
#authorisation
#biosimilarity
#comparability exercise
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”10/1/2026
- Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances10/1/2026
- Swissmedic Portal Release – New Features Available from 23 September 20269/24/2026
- I-SMI.TI.22e Notifications according to Article 41, MPLO9/23/2026
- ElViS 2.09/4/2026